Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
Basel, October 21, 2026 – Novartis announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper. With this approval, Cosentyx becomes the first and only interleukin-17A (IL-17A) inhibitor approved in Europe for adults with PMR.1
Covered in this story
Call it yourself
No calls on $NOVN.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Novartis →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.